Published in Dermatology on February 20, 2008
What causes alopecia areata? Exp Dermatol (2013) 1.14
Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol (2010) 0.78
Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. ScientificWorldJournal (2014) 0.78
Total leukoderma and leukotrichia in a child after hematopoietic SCT: report of a case and review of the literature. Bone Marrow Transplant (2013) 0.77
Chronic graft-versus-host disease mimicking rapid progressive rheumatoid arthritis with atlantoaxial subluxation. BMJ Case Rep (2009) 0.75
Chronic Graft-Versus-Host Disease Mimicking Psoriasis in a Patient with Hemophagocytic Lymphohistiocytosis. Ann Dermatol (2016) 0.75
Successful Repigmentation of Vitiligo after Allogeneic Bone Marrow Transplantation for Hodgkin's Lymphoma by Autologous Noncultured Melanocyte-keratinocyte Transplantation. Indian J Dermatol (2015) 0.75
High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease. Croat Med J (2016) 0.75
Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med (2012) 5.16
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
The shaping of modern human immune systems by multiregional admixture with archaic humans. Science (2011) 2.63
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med (2015) 2.39
Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol (2010) 2.25
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2008) 2.20
Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood (2002) 2.03
Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood (2010) 2.00
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood (2011) 1.75
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol (2011) 1.53
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood (2008) 1.42
NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet α-granules. Nat Genet (2011) 1.38
IMWG consensus on maintenance therapy in multiple myeloma. Blood (2012) 1.29
Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica (2010) 1.27
Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood (2013) 1.26
Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica (2005) 1.21
Autologous bone-marrow mononuclear cell implantation for patients with Rutherford grade II-III thromboangiitis obliterans. J Vasc Surg (2006) 1.19
Hb content-based transfusion policy successfully reduces the number of RBC units transfused. Transfusion (2004) 1.13
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol (2013) 1.07
Adjuvant therapeutic plasma exchange in liver failure: assessments of clinical and laboratory parameters. J Clin Gastroenterol (2008) 1.07
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist (2011) 1.06
Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist (2010) 1.04
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica (2012) 1.03
Late complications after hematopoietic stem cell transplantation. Expert Rev Hematol (2009) 1.03
Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. Haematologica (2013) 1.03
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant (2009) 1.00
Sequence-specific primed PCR (PCR-SSP) typing of HLA Class I and Class II alleles. Methods Mol Med (2007) 0.96
Hyperkeratosis of the nipple associated with chronic graft versus host disease after allogeneic haematopoietic cell transplantation. Acta Derm Venereol (2003) 0.94
Propofol/dexmedetomidine and propofol/ketamine combinations for anesthesia in pediatric patients undergoing transcatheter atrial septal defect closure: a prospective randomized study. Clin Ther (2010) 0.92
Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival. Leuk Lymphoma (2004) 0.91
Expression of IFITM1 in chronic myeloid leukemia patients. Leuk Res (2005) 0.89
Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal stem cells. Stem Cell Rev (2012) 0.89
Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation. Clin Transplant (2003) 0.88
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica (2006) 0.87
Late-onset noninfectious pulmonary complications in adult allogeneic hematopoietic cell transplant recipients. Transplantation (2011) 0.86
Cystatin C can be affected by nonrenal factors: a preliminary study on leukemia. Clin Biochem (2005) 0.85
Effect of methylprednisolone injection speed on the perception of intramuscular injection pain. Pain Manag Nurs (2010) 0.85
Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant (2006) 0.84
An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells. Cytotherapy (2010) 0.84
Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients. Ann Hematol (2011) 0.83
Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy. Eur J Cardiothorac Surg (2009) 0.82
Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther (2015) 0.82
Clinical manifestations of cutaneous graft-versus-host disease after allogeneic haematopoietic cell transplantation: long-term follow-up results in a single Turkish centre. Acta Derm Venereol (2004) 0.82
Congenital multiple clustered dermatofibroma: dermatoscopic findings. Eur J Dermatol (2009) 0.82
Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease. Transfus Apher Sci (2004) 0.81
Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. Am J Hematol (2014) 0.81
Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine. Dig Dis Sci (2002) 0.80
HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO)and use of the Luminex technology. Methods Mol Med (2007) 0.80
Therapeutic plasma exchange in patients with neurological diseases: multicenter retrospective analysis. Transfus Apher Sci (2013) 0.80
Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica (2012) 0.79
Topical cyclosporine-A in dry eye associated with chronic graft versus host disease. Ann Ophthalmol (Skokie) (2010) 0.79
Tunneled catheters placed in bone marrow transplant patients: radiological and clinical follow-up results. Diagn Interv Radiol (2006) 0.79
HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant (2007) 0.79
Dermatomal lichenoid graft-versus-host disease within herpes zoster scars. Int J Dermatol (2003) 0.79
Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma (2007) 0.79
An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration. Leuk Lymphoma (2002) 0.78
Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation. Expert Rev Anti Infect Ther (2011) 0.78
Mycosis fungoides in a patient with ankylosing spondylitis during infliximab therapy. J Drugs Dermatol (2007) 0.78
Familial multiple myeloma associated with disorders of chronic inflammation: first report from Turkey. Clin Lymphoma Myeloma (2008) 0.78
Comparison of hybrid capture and reverse transcriptase polymerase chain reaction methods in terms of diagnosing human cytomegalovirus infection in patients following hematopoietic stem cell transplantation. Saudi Med J (2006) 0.78
Therapeutic plasma exchange in patients with thrombotic thrombocytopenic purpura: a retrospective multicenter study. Transfus Apher Sci (2013) 0.78
How we derived a core curriculum: from institutional to national--Ankara University experience. Med Teach (2004) 0.77
Evaluation of nail involvement in patients with chronic cutaneous graft versus host disease: a single-center study from Turkey. Int J Dermatol (2004) 0.77
High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis. Respirology (2007) 0.77
Review of therapeutic options and the management of patients with myelodysplastic syndromes. Expert Rev Hematol (2013) 0.77
The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy. Transfus Apher Sci (2004) 0.77
Effects of replacement fluids used for therapeutic plasma exchange on plasma viscosity and plasma oncotic pressure. Transfus Apher Sci (2004) 0.77
The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia. Leuk Lymphoma (2003) 0.77
Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra. Transfus Apher Sci (2007) 0.77
Lymphoproliferative disorders in individuals with chronic hepatitis B and C in the Turkish population. J Med Virol (2011) 0.77
Remission of severe autoimmune bullous disorders induced by long-term extracorporeal photochemotherapy. Transfus Apher Sci (2010) 0.77
Plerixafor use in patients with previous mobilization failure: A multicenter experience. Transfus Apher Sci (2012) 0.77
The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD). Transfus Apher Sci (2007) 0.77
Effects of replacement fluids on coagulation system used for therapeutic plasma exchange. Transfus Apher Sci (2003) 0.77
Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases. Transfus Apher Sci (2007) 0.76
Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher (2002) 0.76
Therapeutic Angiogenesis by Autologous Transplantation of Bone Marrow Mononuclear Cells for Buerger's Patients with Retractable Limb Ischaemia: A Preliminary Report. Turk J Haematol (2004) 0.76